<DOC>
	<DOCNO>NCT00861445</DOCNO>
	<brief_summary>The primary purpose investigate safety efficacy SPM927 patient Painful Diabetic Neuropathy</brief_summary>
	<brief_title>A Trial Investigate Safety Efficacy SPM927 Painful Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject clinically diagnose pain attribute diabetic distal sensory motor polyneuropathy 15 year diagnosis diabetes mellitus ( Type I Type II ) . Subjects must least moderate pain ( mean pain intensity ≥ 4 10 baseline week Likert scale ) . subject must good fair diabetic control ( Hgb A1c &lt; 10 % ) Subject condition cause neuropathic pain least severe diabetic pain i.e . peripheral arteriovascular disease . Subject receive treatment seizure . Subject amputation diabeticallyrelated toe amputation . Subject major skin ulcer . Subject clinically significant ECG abnormality . Subject expect take within 7 day prior randomization study : TCAs , mexiletine hydrochloride , lidoderm patch , tramadol , AEDs , dextromethorphan , opioids , capsaicin , nonsteroidal antiinflammatory drug , acetaminophen / paracetamol , skeletal muscle relaxant , benzodiazepine , alpha2agonists ( e.g . clonidine ) , drug indicate sleep disturbance ( e. g. zolpidem tartrate , zaleplon ) overthecounter medication centrally act property . Subject laboratory value outside normal range judge investigator clinically significant . At study entry , subject liver function test value ( AST , ALT , alkaline phosphatase , total bilirubin GGT ) 2 time upper limit normal . subject impaired renal function , i.e. , creatinine clearance lower 60 mL/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Lacosamide , Vimpat®</keyword>
</DOC>